Compass Therapeutics (CMPX) Profit After Tax (2018 - 2026)

Compass Therapeutics has disclosed Profit After Tax across 9 years of filings, most recently posting -$18.3 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$18.3 million, down 10.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$68.2 million (down 23.45% YoY), and the FY2025 annual result was -$66.5 million, down 34.66% from the prior year.
• Profit After Tax came in at -$18.3 million for Q1 2026 at Compass Therapeutics, down from -$15.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$7.2 million in Q1 2022 to a low of -$19.9 million in Q2 2025.
• The 5-year median for Profit After Tax is -$12.0 million (2022), against an average of -$12.7 million.
• Across the five-year window, Profit After Tax sank 100.42% in 2022 and grew 16.79% in 2023, its largest moves.
• Compass Therapeutics' Profit After Tax stood at -$11.6 million in 2022, then decreased by 15.71% to -$13.4 million in 2023, then dropped by 12.06% to -$15.0 million in 2024, then dropped by 4.54% to -$15.7 million in 2025, then retreated by 16.55% to -$18.3 million in 2026.
• The last three Profit After Tax figures came in at -$18.3 million (Q1 2026), -$15.7 million (Q4 2025), and -$14.3 million (Q3 2025), per Business Quant data.